Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda

First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.